SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183

Future Medicinal Chemistry

Volumn 2, Issue 12, 2010, Pages 1751-1759

  Huber, Julie L ^a   McBurney, Michael W ^b   Distefano, Peter S ^a   McDonagh, Thomas ^a,c  

^a Elixir Pharmaceuticals Inc   (United States)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c Adnexus Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ASPARTOACYLASE; ENZYME ACTIVATOR; HISTONE ACETYLTRANSFERASE PCAF; SIRTUIN; SMALL INTERFERING RNA; SRT 1720; SRT 2183; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LYSATE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; GENETIC TRANSFECTION; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACETYLATION; ANIMALS; CELL LINE; ENZYME ACTIVATORS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MICE; SIRTUIN 1; SIRTUINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650184332     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.257     Document Type: Article

References (42)

1. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein SIR2 is an NAD-dependent histone deacetylase. Nature 403, 795-800 (2000). n One of the first reports to show that sirtuins are NAD+-dependent deacetylases.
2. Landry J, Sutton A, Tafrov, ST et al. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc. Natl Acad. Sci. USA 97, 5807-5811 (2000). n One of the first reports to show that sirtuins are NAD+-dependent deacetylases.
3. Borra MT, O'Neill FJ, Jackson MD et al. Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD+- dependent deacetylases. J. Biol. Chem. 277, 12632-12641 (2002).
4. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell 126, 257-268 (2006).
5. Nakahata Y, Kaluzova M, Grimaldi B et al. The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell 134, 329-340 (2008).
6. Asher G, Gatfield D, Stratmann M et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell 134, 317-328 (2008).
7. McBurney MW, Yang X, Jardine K et al. The mammalian SIR2a protein has a role in embryogenesis and gametogenesis. Mol. Cell. Biol. 23, 38-54 (2003).
8. Bordone L, Cohen D, Robinson A et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 6, 759-767 (2007).
9. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH. SIRT1 protects against high-fat diet-induced metabolic damage. Proc. Natl Acad. Sci. USA 105, 9793-9798 (2008).
10. Banks AS, Kon N, Knight C et al. SIRT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 8, 333-341 (2008).
11. Landry J, Slama JT, Sternglanz R. Role of NAD(+) in the deacetylase activity of the SIR2-like proteins. Biochem. Biophys. Res. Commun. 278, 685-690 (2000).
12. Grubisha O, Smith BC, Denu JM. Small molecule regulation of SIR2 protein deacetylases. FEBS J. 272, 4607-4616 (2005).
13. Napper AD, Hixon J, McDonagh T et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 48, 8045-8054 (2005).
14. Howitz KT, Bitterman KJ, Cohen HY et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196 (2003). n First report that resveratrol activates SIRT1.
15. Kaeberlein M, McDonagh T, Heltweg B et al. Substrate specific activation of sirtuins by resveratrol. J. Biol. Chem. 280, 17038-17045 (2005). n One of the reports to show that activation of SIRT1 by resveratrol was an artifact of fluorescence assay methods.
16. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187-17195 (2005). n One of the reports that showed that activation of SIRT1 by resveratrol was an artifact of fluorescence assay methods.
17. Lagouge M, Argmann C, Gerhart-Hines Z et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1a. Cell 127, 1109-1122 (2006).
18. Beher D, Wu J, Cumine S et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 74, 619-624 (2009).
19. Milne JC, Lambert PD, Schenk S et al. Small molecule activators of SIRT1 as therapeutics for the treatment of Type 2 diabetes. Nature 450, 712-716 (2007). n Report of small molecule SIRT1 activators that are more potent than resveratrol.
20. Pacholec M, Chrunyk B, Cunningham D et al. SRT1720, SRT2183, SRT1460 and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 285, 8340-8351 (2010). n Report refuting the claim of [19] that these molecules directly activate SIRT1. As with resveratrol, the results were suggested to be due to fluorescence-based assay artifacts.
21. McDonagh T, Hixon J, DiStefano PS, Curtis R, Napper AD. Microplate filtration assay for nicotinamide release from NAD using a boronic acid resin. Methods 36, 346-350 (2005).
22. Solomon JM, Pasupuleti R, Xu L et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell. Biol. 26, 28-38 (2006).
23. Trievel RC, Li FY, Marmorstein R. Application of a fluorescent histone acetyltransferase assay to probe the substrate specificity of the human p300/CBP-associated factor. Anal. Biochem. 287, 319-328 (2000).
24. Dai H, Kustigian L, Carney D et al. SIRT1 activation by small molecules - kinetic and biophysical evidence for direct interaction of enzyme and activator. J. Biol. Chem. 285(43), 32695-32703 (2010) (Epub).
25. Ahn B-H, Kim H-S, Song S et al. A role for the mitochondrial deacetylase SIRT3 in regulating energy homeostasis. Proc. Natl Acad. Sci. USA 105, 14447-14452 (2008).
26. Cimen H, Han MJ, Tong Q, Koc H, Koc EC. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry 49, 304-311 (2010).
27. Schwer B, Bunkenborg J, Verdin RO, Andersen JS, Verdin E. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc. Natl Acad. Sci. USA 103, 10224-10229 (2006).
28. Hallows WC, Lee S, Denu JM. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc. Natl Acad. Sci. USA 103, 10230-10235 (2006).
29. Yang Y, Cimen H, Han M-J et al. NAD+- dependent deacetylase SIRT3 regulates mitochondrial protein synthesis by deacetylation of the ribosomal protein MRPL10. J. Biol. Chem. 285, 7414-7429 (2010).
30. Kim HS, Patel K, Muldoon-Jacobs K et al. SIRT3 is a mitochondria- localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17, 41-52 (2010).
31. Luo J, Nikolaev AY, Imai S-I et al. Negative control of p53 by SIR2a promotes cell survival under stress. Cell 107, 137-148 (2001).
32. Vaziri H, Dessain SK, Eaton EN et al. hSIR2 (SIRT1) functions as an NADdependent p53 deacetylase. Cell 107, 149-159 (2001).
33. Cheng HL, Mostoslavsky R, Saito S et al. Developmental defects and p53 hyperacetylation in SIR2 homolog (SIRT1)- deficient mice. Proc. Natl Acad. Sci. USA 100, 10794-10799 (2003).
34. Funk JA, Odejinmi S, Schnellmann RG. SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. J. Pharmacol. Exp. Ther. 333, 593-601 (2010).
35. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606 (1997).
36. Liu Y, Dentin R, Chen D et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 456, 269-273 (2008).
37. Lerin C, Rodgers JT, Kalume DE, Kim SH, Pandey A, Puigserver P. GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1a. Cell Metab. 3, 429-438 (2006).
38. Kemper JK, Xiao Z, Ponugoti B et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 10, 392-404 (2009).
39. Yamauchi T, Oike Y, Kamon J et al. Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nature Genetics 30, 221-226 (2002).
40. Balasubramanyam K, Varier RA, Altaf M et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferasedependent chromatin transcription. J. Biol. Chem. 279, 51163-51171 (2004).
41. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinol. 149, 3549-3558 (2008).
42. Feige JN, Lagouge M, Canto C et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 8, 347-358 (2008).